4 completed, 2 recruiting, 1 active not recruiting. 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow somatrogon: new trials by email Literature Review of somatrogon trials Research Report on somatrogon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature. Somatrogon, Genotropin - ISS, SGA | Phase 3 | Recruiting | Rabin Medical Center | 254 | 2026-02-01 | 2026-04-30 |
| A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India. Somatrogon - Dwarfism, Pituitary | Recruiting | Pfizer | 50 | 2025-01-30 | 2026-09-24 | |
| Ngenla Subcutaneous Injection Special Investigation NGENLA (Somatrogon) - Growth Hormone Deficiency Without Epiphyseal Closure | Active not recruiting | Pfizer | 1 | 2023-02-06 | 2026-10-07 | |
| Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD Genotropin, somatrogon - Growth Hormone Deficiency | Phase 3 | Completed | Pfizer | 87 | 2019-02-07 | 2021-10-14 |
| A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations Somatrogon - Healthy Male Volunteers | Phase 1 | Completed | OPKO Health, Inc. | 49 | 2019-01-18 | 2020-04-28 |
| Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency MOD-4023, Genotropin - Growth Hormone Deficiency | Phase 3 | Completed | OPKO Health, Inc. | 44 | 2017-12-07 | 2021-08-12 |
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children MOD-4023, Somatropin - Pediatric Growth Hormone Deficiency | Phase 3 | Completed | OPKO Health, Inc. | 224 | 2016-12-01 | 2025-07-20 |
OPKO Health, Inc. (3) · Pfizer (3) · Rabin Medical Center (1)
United States (4) · India (3) · Japan (3) · Bulgaria (2) · Israel (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belarus (1) · Canada (1) · Colombia (1) · Czechia (1) · France (1) · Georgia (1) · Greece (1)
Moshe Phillip, Professor (1) · Reiko Horikawa, M.D, Ph. D. (1) · Sandra Pagnusset, MD (1) · Tony Cruz (1)
PMID 35405011, PMID 37955005, PMID 38053515, PMID 38717038, PMID 41183961
2018 (1)